Cardiovascular Business · 16 Sep, 17:03 · Business briefing

Johnson & Johnson appears to exit LAA closure market, selling heart tech to new startup

Johnson & Johnson is reportedly withdrawing from the left atrial appendage closure market by divesting its heart technology assets to a newly formed startup.

What it means for you ↓ Courses for this story

26%average salary uplift after a professional certificate

2.7xfaster promotion for certified professionals

71%of leaders prefer candidates who upskill continuously

20days to your first credential

The briefing

The story
in brief.

What happened, who it affects, and why it landed on our intelligence desk — in plain English, sixty seconds or less.

Johnson & Johnson is reportedly withdrawing from the left atrial appendage closure market by divesting its heart technology assets to a newly formed startup. This strategic move signals a significant shift in the cardiovascular device sector, as the pharmaceutical and medical giant reallocates resources away from this specific therapeutic area. For industry observers, the transaction highlights the increasing trend of large corporations exiting niche markets to focus on core competencies, while enabling agile startups to acquire established technology and accelerate market entry. The deal underscores the dynamic nature of healthcare innovation, where intellectual property and regulatory approvals become key assets for emerging competitors seeking to challenge incumbent players in cardiac care.

Employer demand for Healthcare Management skills — indexed growth since 2019
Indicative index of skill mentions in professional job postings for the field this story moves (2019 = 1)

Your move

What this means
for your career.

Every headline redistributes opportunity. Here is who this one rewards — and how to be on the right side of it.

This development signals a shift in the cardiovascular sector, where agility and specialised expertise now outweigh brand legacy. You should prioritise skills in regulatory affairs and medical device commercialisation, as startups require rapid market entry strategies. Professionals in healthcare management and innovation must adapt to a landscape where big pharma exits create opportunities for nimble competitors. Focus on understanding the lifecycle of medical technologies and the regulatory pathways for novel devices. If you work in strategy or sales, prepare for increased competition from well-funded startups leveraging acquired IP. Develop capabilities in M&A integration and niche market analysis to remain relevant. Ultimately, cultivate a mindset that values adaptability and deep technical knowledge over corporate stability, positioning yourself to thrive in this evolving ecosystem.

For this story, the fields that convert it into pay are Healthcare Management, Innovation, Business And Management and Compliance And Governance — exactly the programmes matched below. The chart shows the indicative salary uplift certified professionals report in each of those fields; every one of them is a click away, from £79, finishing in as few as 20 days.

Indicative salary uplift in the fields matched to this story
Indicative ranges from published continuing-education salary studies, by field — each field is a recommended course below

Matched to this story

Enrol in these
to benefit.

These programmes position you for exactly this shift — online, self-paced, and finishing with a verifiable certificate you can share the day you pass.